vs
Side-by-side financial comparison of Axil Brands, Inc. (AXIL) and OCULAR THERAPEUTIX, INC (OCUL). Click either name above to swap in a different company.
OCULAR THERAPEUTIX, INC is the larger business by last-quarter revenue ($13.3M vs $8.1M, roughly 1.6× Axil Brands, Inc.). Axil Brands, Inc. runs the higher net margin — 8.7% vs -488.0%, a 496.6% gap on every dollar of revenue. On growth, Axil Brands, Inc. posted the faster year-over-year revenue change (5.2% vs -22.4%). Axil Brands, Inc. produced more free cash flow last quarter ($906.4K vs $-57.1M). Over the past eight quarters, Axil Brands, Inc.'s revenue compounded faster (12.1% CAGR vs -5.3%).
Axil Brands, Inc. is a U.S.-headquartered company that designs, manufactures and markets premium hearing protection products, audio enhancement devices and personal audio accessories. Its offerings include custom-fit earplugs, Bluetooth-enabled hearing buds for work, sports and leisure use, serving both consumer and professional segments across global markets.
Ocular Therapeutix, Inc. is a biopharmaceutical firm specializing in developing and commercializing innovative ophthalmic therapies. Its products treat acute and chronic eye conditions including post-surgical pain, glaucoma, and dry eye, serving patients and ophthalmology providers primarily across the U.S. and select global markets.
AXIL vs OCUL — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.1M | $13.3M |
| Net Profit | $704.9K | $-64.7M |
| Gross Margin | 68.1% | 88.0% |
| Operating Margin | 11.1% | -526.5% |
| Net Margin | 8.7% | -488.0% |
| Revenue YoY | 5.2% | -22.4% |
| Net Profit YoY | 11.2% | -33.6% |
| EPS (diluted) | $0.09 | $-0.27 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $8.1M | $13.3M | ||
| Q3 25 | $6.9M | $14.5M | ||
| Q2 25 | $5.8M | $13.5M | ||
| Q1 25 | $6.9M | $10.7M | ||
| Q4 24 | $7.7M | $17.1M | ||
| Q3 24 | $5.9M | $15.4M | ||
| Q2 24 | $6.5M | $16.4M | ||
| Q1 24 | $6.5M | $14.8M |
| Q4 25 | $704.9K | $-64.7M | ||
| Q3 25 | $334.3K | $-69.4M | ||
| Q2 25 | $-245.6K | $-67.8M | ||
| Q1 25 | $576.7K | $-64.1M | ||
| Q4 24 | $633.7K | $-48.4M | ||
| Q3 24 | $-109.8K | $-36.5M | ||
| Q2 24 | $49.5K | $-43.8M | ||
| Q1 24 | $781.1K | $-64.8M |
| Q4 25 | 68.1% | 88.0% | ||
| Q3 25 | 67.6% | 87.8% | ||
| Q2 25 | 70.0% | 85.6% | ||
| Q1 25 | 71.7% | 88.2% | ||
| Q4 24 | 71.1% | 92.8% | ||
| Q3 24 | 71.0% | 89.9% | ||
| Q2 24 | 71.5% | 90.8% | ||
| Q1 24 | 71.5% | 91.0% |
| Q4 25 | 11.1% | -526.5% | ||
| Q3 25 | 6.0% | -472.3% | ||
| Q2 25 | 0.8% | -502.6% | ||
| Q1 25 | 8.4% | -597.5% | ||
| Q4 24 | 8.7% | -296.1% | ||
| Q3 24 | -2.4% | -298.2% | ||
| Q2 24 | 2.6% | -265.1% | ||
| Q1 24 | -1.6% | -214.0% |
| Q4 25 | 8.7% | -488.0% | ||
| Q3 25 | 4.9% | -477.3% | ||
| Q2 25 | -4.3% | -503.9% | ||
| Q1 25 | 8.3% | -598.7% | ||
| Q4 24 | 8.2% | -283.3% | ||
| Q3 24 | -1.9% | -236.6% | ||
| Q2 24 | 0.8% | -266.3% | ||
| Q1 24 | 12.1% | -438.9% |
| Q4 25 | $0.09 | $-0.27 | ||
| Q3 25 | $0.04 | $-0.38 | ||
| Q2 25 | $-0.03 | $-0.39 | ||
| Q1 25 | $0.07 | $-0.38 | ||
| Q4 24 | $0.08 | $-0.25 | ||
| Q3 24 | $-0.02 | $-0.22 | ||
| Q2 24 | $0.11 | $-0.26 | ||
| Q1 24 | $0.04 | $-0.49 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.0M | $737.1M |
| Total DebtLower is stronger | $138.3K | — |
| Stockholders' EquityBook value | $11.1M | $654.3M |
| Total Assets | $16.2M | $808.1M |
| Debt / EquityLower = less leverage | 0.01× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.0M | $737.1M | ||
| Q3 25 | $4.1M | $344.8M | ||
| Q2 25 | $4.8M | $391.1M | ||
| Q1 25 | $4.7M | $349.7M | ||
| Q4 24 | $5.2M | $392.1M | ||
| Q3 24 | $4.1M | $427.2M | ||
| Q2 24 | $3.3M | $459.7M | ||
| Q1 24 | $4.9M | $482.9M |
| Q4 25 | $138.3K | — | ||
| Q3 25 | $139.2K | — | ||
| Q2 25 | $140.2K | — | ||
| Q1 25 | $141.0K | — | ||
| Q4 24 | $143.3K | — | ||
| Q3 24 | $144.3K | — | ||
| Q2 24 | $146.6K | — | ||
| Q1 24 | — | — |
| Q4 25 | $11.1M | $654.3M | ||
| Q3 25 | $10.2M | $258.2M | ||
| Q2 25 | $9.7M | $305.9M | ||
| Q1 25 | $9.7M | $265.9M | ||
| Q4 24 | $8.8M | $315.3M | ||
| Q3 24 | $7.9M | $352.0M | ||
| Q2 24 | $7.7M | $377.7M | ||
| Q1 24 | $8.8M | $408.0M |
| Q4 25 | $16.2M | $808.1M | ||
| Q3 25 | $15.4M | $410.9M | ||
| Q2 25 | $12.9M | $451.3M | ||
| Q1 25 | $13.0M | $405.9M | ||
| Q4 24 | $13.7M | $457.9M | ||
| Q3 24 | $11.4M | $490.4M | ||
| Q2 24 | $11.0M | $517.1M | ||
| Q1 24 | $12.7M | $538.9M |
| Q4 25 | 0.01× | — | ||
| Q3 25 | 0.01× | — | ||
| Q2 25 | 0.01× | — | ||
| Q1 25 | 0.01× | — | ||
| Q4 24 | 0.02× | — | ||
| Q3 24 | 0.02× | — | ||
| Q2 24 | 0.02× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $934.8K | $-54.2M |
| Free Cash FlowOCF − Capex | $906.4K | $-57.1M |
| FCF MarginFCF / Revenue | 11.1% | -430.9% |
| Capex IntensityCapex / Revenue | 0.3% | 21.4% |
| Cash ConversionOCF / Net Profit | 1.33× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-216.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $934.8K | $-54.2M | ||
| Q3 25 | $-739.2K | $-50.7M | ||
| Q2 25 | $194.4K | $-55.2M | ||
| Q1 25 | $-169.9K | $-44.7M | ||
| Q4 24 | $1.0M | $-39.4M | ||
| Q3 24 | $897.3K | $-36.6M | ||
| Q2 24 | $-336.6K | $-24.8M | ||
| Q1 24 | $-912.8K | $-33.9M |
| Q4 25 | $906.4K | $-57.1M | ||
| Q3 25 | $-747.6K | $-56.7M | ||
| Q2 25 | — | $-56.5M | ||
| Q1 25 | $-258.2K | $-46.6M | ||
| Q4 24 | $941.1K | $-39.6M | ||
| Q3 24 | — | $-36.6M | ||
| Q2 24 | $-394.9K | $-25.5M | ||
| Q1 24 | $-922.1K | $-34.1M |
| Q4 25 | 11.1% | -430.9% | ||
| Q3 25 | -10.9% | -390.0% | ||
| Q2 25 | — | -419.7% | ||
| Q1 25 | -3.7% | -435.6% | ||
| Q4 24 | 12.2% | -232.0% | ||
| Q3 24 | — | -237.6% | ||
| Q2 24 | -6.1% | -155.4% | ||
| Q1 24 | -14.3% | -231.1% |
| Q4 25 | 0.3% | 21.4% | ||
| Q3 25 | 0.1% | 41.2% | ||
| Q2 25 | — | 9.3% | ||
| Q1 25 | 1.3% | 18.1% | ||
| Q4 24 | 0.9% | 1.2% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | 0.9% | 4.5% | ||
| Q1 24 | 0.1% | 1.7% |
| Q4 25 | 1.33× | — | ||
| Q3 25 | -2.21× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.29× | — | ||
| Q4 24 | 1.59× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -6.80× | — | ||
| Q1 24 | -1.17× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXIL
| Hearing Enhancement And Protection | $7.8M | 95% |
| Other | $378.9K | 5% |
OCUL
Segment breakdown not available.
